<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02802475</url>
  </required_header>
  <id_info>
    <org_study_id>MEC 2014-463</org_study_id>
    <nct_id>NCT02802475</nct_id>
  </id_info>
  <brief_title>Antibodies Causing Epilepsy Syndromes: The ACES Study.</brief_title>
  <acronym>ACES</acronym>
  <official_title>Antibodies Causing Epilepsy Syndromes: The ACES Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nationaal Epilepsie Fonds</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <brief_summary>
    <textblock>
      The Antibodies Causing Epilepsy Syndromes (ACES) Study is a observational cohort study
      focusing on detection of auto-immune epilepsy in patients with epilepsy of unknown origin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently new treatable causes of epilepsy have been identified. These disorders are caused by
      a disruption of the balance in the brain caused by inflammation. This inflammatory reaction
      is caused by an autologous reaction of the immune system to specific brain proteins. The body
      produces antibodies to specific parts of the brain. These disorders can lead to epilepsy,
      memory dysfunction and psychiatric problems. Recognition is necessary for good treatment.
      Mostly anti-epileptic drugs are insufficient. These diseases can be treated with
      immune-modulating therapy. The ACES Study will focus on determining the frequencies of known
      antibodies and finding new, currently unknown, antibodies, causing epilepsy. Therefore
      patients will be investigated with epilepsy of unknown origin. To find new antibodies sera of
      patients with epilepsy will be added to brain sections of rats and to cultivated neuronal
      cells to look for a reaction. If new antibodies will be detected clinical features will be
      mapped of the patients. Also effects of antibodies on brain cells will be determined.
      Discovery of new antibodies can provide new treatment options for these patients. Also it
      will enable to discover more about the pathologic mechanisms of epilepsy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>frequency of patients with known and novel antibodies</measure>
    <time_frame>3 year</time_frame>
    <description>detection of specific known and novel, currently unknown, auto-antibodies by immunohistochemistry, live hippocampal neuron cultures and cell-based assay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>modified Rankin scale</measure>
    <time_frame>1 year</time_frame>
    <description>outcome 1 year after inclusion in the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure frequency</measure>
    <time_frame>1 year</time_frame>
    <description>seizure frequency 1 year after inclusion in the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment response</measure>
    <time_frame>3 months</time_frame>
    <description>frequency of objective improvement of outcome (seizure frequency, modified Rankin Scale) after immunotherapy, as compared to matched controls (without antibodies) from our study to exclude an effect due to regression to the mean or natural nistory.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Auto-immune Encephalitis</condition>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>acquired chronic, focal, epilepsy</arm_group_label>
    <description>patients ≥18 years of age, with acquired chronic epilepsy of unknown origin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>new onset epilepsy</arm_group_label>
    <description>patients ≥18 years of age, with new onset status epilepticus or new onset seizures with suspicion of limbic encephalitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>vena punction</intervention_name>
    <arm_group_label>acquired chronic, focal, epilepsy</arm_group_label>
    <arm_group_label>new onset epilepsy</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum and (if available) CSF
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with acquired chronic focal epilepsy without known cause or new onset status
        epilepticus or new onset seizures with signs of encephalitis and unknown cause.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 18 and older.

          -  Status epilepticus or new onset seizures with signs of limbic encephalitis (clinical
             picture, MRI (FLAIR abnormalities), EEG abnormalities or CSF findings (CSF
             pleocytosis, increased IgG index, oligoclonal bands), or:

          -  Patients with acquired chronic focal epilepsy with an unknown cause.

        Exclusion Criteria:

          -  Children

          -  Epilepsy with known cause
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maarten J Titulaer, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marienke AA de Bruijn, MD</last_name>
    <phone>0031628306007</phone>
    <email>aces@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maarten J Titulaer, MD, PhD</last_name>
    <phone>0031628306007</phone>
    <email>aces@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Epilepsiecentrum Kempenhaeghe</name>
      <address>
        <city>Heemstede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H JM Majoie</last_name>
      <email>majoiem@kempenhaeghe.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stichting Epilepsie Instelling Nederland (SEIN)</name>
      <address>
        <city>Heemstede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R D Thijs</last_name>
      <email>rthijs@sein.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Academic Hospital Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R Rouhl</last_name>
      <email>r.rouhl@mumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M AA de Bruijn</last_name>
      <email>aces@erasmusmc.nl</email>
    </contact>
    <contact_backup>
      <last_name>M J Titulaer</last_name>
      <email>aces@erasmusmc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Maasstad Hospital</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C A van Donselaar</last_name>
      <email>donselaarc@maasstadziekenhuis.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haga Hospital</name>
      <address>
        <city>The Hague</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P W Wirtz</last_name>
      <email>p.wirtz@hagaziekenhuis.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth Hospital</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J TH van Asseldonk</last_name>
      <email>t.v.asseldonk@elisabeth.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMCU</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leijten, Prof</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2016</study_first_submitted>
  <study_first_submitted_qc>June 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>M.J. Titulaer</investigator_full_name>
    <investigator_title>MD. PhD.</investigator_title>
  </responsible_party>
  <keyword>antibodies</keyword>
  <keyword>auto-immune encephalitis</keyword>
  <keyword>epilepsy</keyword>
  <keyword>limbic encephalitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Hashimoto Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

